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Abstract
Background: Bovine herpesvirus 1 (BoHV1) is a member of the viral subfamily of Alphaherpesvirinae that infects
various species, including cattle, sheep, and goats. The virus causes infectious bovine rhinotracheitis (IBR), which is
included in a European list of diseases that may require control and eradication programs. The lack of confirmatory
tests affects the validity of diagnostic tools, especially those used for vaccinated herds. In this study, we report the
development and validation of an indirect enzyme-linked immunosorbent assay (ELISA) based on BoHV1
glycoprotein E, which was expressed as a secreted recombinant antigen in a mammalian cell system. The
performance of the new rec-gE ELISA was compared with that of commercially available indirect and/or blocking
ELISAs.
Results: The sample set included blood sera from animals from IBR-positive farms, IBR-free farms, and marker-vaccinated
farms. The indirect ELISA proposed in this study is based on antibody reactivity against BoHV1 gE, and showed high
sensitivity and specificity (98.41 and 99.76 %, respectively).
Conclusions: The ELISA performed well, in terms of both its diagnostic sensitivity and specificity, and as a confirmatory
methodology, and therefore should improve the diagnostic protocols used for IBR surveillance.
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Background
Bovine herpesvirus 1 (BoHV1) is a member of the viral
subfamily of Alphaherpesvirinae that infects different
species, including cattle, sheep, and goats. The respira-
tory syndrome produced in cattle is known as infectious
bovine rhinotracheitis (IBR), and genital infections are
associated with pustular vulvovaginitis, balanoposthitis,
and abortion. Both the respiratory syndrome and genital
infection may cause lifelong latent infection. The virus is
self-reactivating or is reactivated by stress [1] or treat-
ment with corticosteroids [2], causing relapse. Although
mortality is low, the disease has a severe impact on
growth, milk production, and the international livestock
trade, causing it to be included in a European list of
diseases that may require control and eradication programs
(64/432/CEE [3]).
The epidemiological situation varies across different
countries [1]. In response to European Union (EU) regu-
lations, several European countries have adopted differ-
ent strategies for the eradication of IBR, and several
countries have achieved an IBR-free status (Sweden,
Austria, Denmark, Finland, Switzerland, Norway, the
Federal State of Bavaria, and the Province of Bolzano in
Italy) and have established trade restrictions for sero-
positive animals (2004/558/CEE [4]).
A glycoprotein E (gE)-negative strain of BoHV1 has
been shown to be an effective and safe tool for IBR con-
trol [5] and reduces the shedding of viral particles [6, 7].
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The use of DIVA (differentiation of infected from
vaccinated animals) vaccines and planning surveillance
measures [1, 8] should allow the serological differenti-
ation of infected and vaccinated cattle [9–11].
Because the most common approach to BoHV1 con-
trol involves the use of gE-deleted vaccines [10, 12],
serological studies are based on a combination of whole-
virus-based indirect ELISA or gB-based blocking ELISA,
together with a gE-based blocking ELISA. The gE ELISA
approach includes blocking assays that were developed
using a monoclonal antibody that recognizes a single
conformational epitope present on the gI–gE complex in
the wild-type virus [13]. However, it has been demon-
strated that some gE-blocking ELISAs are not absolutely
specific and sensitive [14]. In some cases, hypervacci-
nated animals can give false-positive results attributable
to nonspecific blocking, caused by the steric hindrance
afforded by the high antibody titers against other BoHV1
glycoproteins, such as gB, gC, gD, and gI [13, 15]. Such
false-positive reactions can also occur when testing
“fresh” sera because of a phenomenon that occurs in
samples that are not frozen and heat-inactivated, as was
suggested for the BoHV1 gE ELISAs [16]. In contrast,
comparison of the gE ELISA with the highly sensitive gB
ELISA [14] showed the 98 % relative sensitivity of the
diagnostic protocol [13]. Reference sera were selected, so
that competitive serological test procedures could be
performed with stable references [17]. Despite the use of
these sera in all validation processes, an evaluation of
the diagnostic tests conducted in 2001 and published
three years later suggested that the standardization and
harmonization of the tests should be ongoing, and per-
formed with increased numbers of reference sera [14].
To our knowledge, the only commercially available tests
capable of discriminating between infected and vacci-
nated animals during immunization programs are block-
ing ELISAs. Diagnostic test performance is especially
important during the last phases of eradication pro-
grams, and confirmatory tests are required to clarify
possibly doubtful results. In this study, we developed
and validated an indirect ELISA based on BoHV1 gE
expressed as a secreted recombinant antigen in a mam-
malian cell system.
Results and discussion
In total, 189 field sera were classified as positive with
different commercial ELISAs, based on both indirect
and blocking approaches. Of these, 186 were positive
when tested with the rec-gE ELISA. A single serum was
positive on the IDEXX Trachitest Serum Screening Ab
Test and on IDEXX IBR gB and rec-gE ELISAs, but was
negative on the IDEXX IBR gE Ab blocking ELISA test.
All three positive samples that were incorrectly classified
with the rec-gE ELISA were identified as positive with
both the indirect and the gB and gE blocking ELISAs.
All seven sera collected after experimental infection
were tested with both the IDEXX gE blocking ELISA
and the rec-gE indirect ELISA. Each serum was diluted
to test the analytical sensitivity. The rec-gE ELISA
showed good precocity, classifying samples as positive
32 days after infection when diluted 1:4 (Fig. 1). Three
different field sera were serially diluted with the same
procedure before testing, to simulate different antibody
titer scenarios. Clearly, the antibody titer strongly influ-
enced the analytical sensitivity. The blocking ELISA
identified the diluted sera as positive at higher dilutions
than the rec-gE indirect ELISA in all cases (Fig. 2). The
results obtained from pooled samples can be interpreted
using different cut-off settings [18]. Therefore, we
evaluated the performance of the new rec-gE ELISA on
pooled blood serum samples, so that the cut-off level
could be modified based on the pool size to improve its
analytical sensitivity.
In total, 459 of 460 serum samples from gE-negative an-
imals were negative on the rec-gE ELISA. Among the
negative samples, a small subset (n = 16) showed reactivity
when tested with the Hipra commercial gE blocking
ELISA. All these samples were negative when tested with
other commercial ELISAs (both indirect and blocking as-
says) or with the rec-gE ELISA. Only one serum from the
IBR-free herd showed reactivity for the rec-gE ELISA,
leading to a false-positive outcome. Interestingly, the false-
positive results were different in the two tests, confirming
the independence of the two approaches. The false-
positive results in the two tests are shown in Fig. 3. The
reactivity distribution of the sera tested with the rec-gE
ELISA is shown in Fig. 4a. A receiver operating character-
istic (ROC) curve analysis showed that the best cut-off
value was 80 % of the positive control reactivity included
in each plate (Fig. 4b). From this starting point, we
calculated diagnostic sensitivity and specificity values of
98.41 % (95 % confidence interval [CI] 95.43–99.67 %)
and 99.76 % (95 % CI 98.79–99.99 %), respectively.
In sequential testing, when positive results from the
first analysis are assessed again with an independent test,
the net effect is to increase the specificity and positive
predictive value because each case is classified as posi-
tive on multiple tests (so false-positive results are rare).
Therefore, an independent test should be used to con-
firm the positive results obtained with a blocking ELISA
when screening herds, especially during the last phases
of an eradication program. When the prevalence of the
disease was low (less than 5 %), the proposed rec-gE
ELISA achieved high positive and negative predictive
values of 94.5 and 99.9 %, respectively. The rec-gE
ELISA also seemed to show good precocity, similar to
that of the commercial gE blocking ELISA.
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The surveillance of IBR in IBR-free herds or regions is
easily performed because there is a complete lack of
antibodies against the viral proteins in unvaccinated,
susceptible animals. If a wild-type viral strain should
spread to the farm, the resulting massive immune re-
sponse would be readily detectable. Whole-virus indirect
ELISAs are commercially available and perform very well
in the detection of BoHV1 antibodies. However, al-
though vaccines confer obvious advantages in control-
ling viral spread within and among farms, vaccination
programs can entail some pitfalls, especially during the
last phases of an eradication program. In the last two
decades, DIVA vaccines for IBR have been used as com-
panion tests based on gE blocking ELISAs. The tests are
very effective, but several factors must be considered.
The most important involves confirmatory tests, which
have been unavailable until now, but are essential during
the last phases of an eradication program. It is well doc-
umented that the combination of gB and gE blocking
ELISAs is an efficient way to control IBR on IBR-free
Fig. 2 Analytical sensitivity. Field sera a, b, and c were serially diluted with negative serum and tested with the blocking ELISA (black circles) and
the rec-gE indirect ELISA (white circles). The gray area shows the window of uncertainty in the interpretation of the results for the blocking ELISA.
The optimal cut-off for the rec-gE ELISA should be reevaluated (see Discussion)
Fig. 1 Seroconversion of experimentally infected animals. Sera were tested with the blocking ELISA (black circles) and the rec-gE indirect ELISA
(white circles). The gray area shows the window of uncertainty in the interpretation of results for the blocking ELISA. The horizontal dashed line
indicates the cut-off for the rec-gE ELISA
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and vaccinated farms [1, 19], but in both cases, some
problems can arise. Blocking ELISAs based on reactivity
against gB can suffer from less-than-absolute specificity
when alphaherpesviruses genetically related to BoHV1
are circulating on the farm. For example, their partial
cross-reactivity with antibodies directed against Bovine
herpesvirus 2 [18] or Bubaline herpesvirus 1 [20] can re-
sult in IBR-positive outcomes on the gB blocking ELISA
and lead to “vaccination-like” behavior. Consequently,
the official procedures and restrictions prescribed by EU
regulations should be applied in IBR-free regions (2004/
558/CEE [4]).
The same scenario can occur on vaccinated farms,
where a gE blocking ELISA can return false-positive re-
sults in hypervaccinated animals because of the steric
hindrance of antibodies directed against viral proteins
Fig. 3 IBR-false-positive sera. Reactivity of sera showing false-positive results when tested with the blocking ELISA (black circles) and the
rec-gE indirect ELISA (white circles). The gray area shows the window of uncertainty in the interpretation of the results for the blocking
ELISA. The horizontal dashed line indicates the cut-off for the rec-gE ELISA
Fig. 4 Results of the rec-gE ELISA. a Distribution of the reactivity of the tested sera; the horizontal dashed line indicates the cut-off for the rec-gE
ELISA. b ROC curve showing the best sensitivity/specificity compromise (black dot). A magnification of the high-performance region is boxed
within the graph
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other than gE. Some sera from farms with a long history
of immunization with DIVA vaccines and where the risk
of viral circulation was very low produced positive re-
sults when tested with a commercial gE blocking ELISA.
Further tests showed the true negative status of these
samples, confirming the results obtained with the rec-gE
indirect ELISA.
The indirect ELISA described in this study, based on
the reactivity of IBR-infected animals to the gE protein
only, performed well, and most importantly, seemed to
be robust in the critical situations described above. No
cross-reaction was observed with alphaherpesviruses
that are genetically related to BoHV1 [20, 21] and no
false-positive results were obtained in vaccinated herds.
It is interesting to note that rec-gE does not express
the conformational epitope that is recognized by the
monoclonal antibody used in the blocking ELISA, con-
firming that gI is required to detect diagnostic antibodies
in blocking assays [21]. This strongly supports the inde-
pendent nature of the rec-gE indirect ELISA. However,
although gI is less immunogenic than other viral glyco-
proteins because of its proximity to gE, it may be re-
sponsible for potential false-positive reactions in
blocking ELISAs when hypervaccinated animals are
tested shortly after vaccination, which arises from steric
hindrance.
The ectodomain of gE exposes different epitopes and
this could explain its excellent sensitivity and diagnostic
precocity. This aspect of the protein is particularly im-
portant in terms of herd surveillance, allowing the early
diagnosis of new seroconversions that occur before the
virus has spread rapidly within a farm. However, several
points must be taken into account if a comparison be-
tween independent tests is to be made. Reference sera
are one such important point. The sera used as refer-
ences for blocking ELISAs (Perrin et al. 1994) may not
be suitable for comparing the sensitivity of the rec-gE
test with that of commercial blocking ELISAs because
their reaction mechanisms are independent and different
serum volumes are used in the two assays (50 μl in the
blocking ELISAs and 10 μl in the rec-gE ELISA). Fur-
thermore, the antibody titers seem to influence the
sensitivity of this test because the rec-gE ELISA failed to
identify diluted positive samples of field sera.
Conclusions
Several European countries have implemented different
surveillance and control programs to eradicate IBR, but
the current economic insecurity has caused a reduction
in the funds available to control infectious diseases in
farm animals. Therefore, it is very important to improve
the set of tools available, to identify the correct surveil-
lance strategy, and to determine whether blood serum is
the best diagnostic sample. Several studies have assessed
the feasibility of using milk samples, especially from bulk
milk, as a source of antibodies for IBR control. In IBR-
free geographic areas, surveillance can be undertaken
with commercially available tests, but in herds where
DIVA vaccination is performed, blocking ELISAs can
show low sensitivity and specificity. Further studies will
evaluate the use of this rec-gE indirect ELISA in bulk
milk testing.
Methods
Antigen preparation and ELISA procedure
To isolate the full-length BoHV1 gE gene, DNA was ex-
tracted from Madin–Darby bovine kidney (MDBK) cell
cultures infected with a field strain of BoHV1 using a
DNeasy Blood and Tissue Kit (Qiagen, Hilden,
Germany). The DNA was used as the template in a
PCR reaction. To clone and express the ectodomain of
the protein a primer set was designed to bind down-
stream from the signal peptide (predicted with the
SignalP4.0 software) and 14 residues upstream from the
putative transmembrane domain (predicted with the
Expasy TMpred tool). To facilitate directional cloning,
each primer contained an appropriate restriction site
(underlined) at the 5’ terminus (forward primer, BamHI
restriction site: 5’-TTGGATCCTAAGCCCGCGACC-
GAAACCC-3’; reverse primer, XhoI restriction site: 5’-
TTCTCGAGTCTCGCTGGTGAGCGGTGGGC-3’).
The LongRange PCR Kit (Qiagen) was used to amplify
the targeted gene region, following the standard proto-
col proposed by the manufacturer. The amplified prod-
uct of the expected length was column purified
(NucleoSpin® Extract II Kit; Macherey-Nagel, Germany)
and directly sequenced (BMR Genomics, Padua, Italy)
using the PCR primers. The amplified gene fragment
was digested with the appropriate restriction enzymes
(Thermo Scientific) and ligated into the pSecTag2/
Hygro plasmid (Invitrogen, USA), to allow the efficient
intracellular sorting of the expressed protein and its se-
cretion into the medium of transiently transfected
mammalian cells. Ligation product was used to trans-
form competent Escherichia coli (strain JM109) cells,
and ampicillin-resistant colonies were rapidly screened
with PCR and directly sequenced to confirm the au-
thenticity and in-frame insertion of each fragment. The
plasmid was purified from 25 ml of LB culture
(~100 mg) using the Qiagen Plasmid Midi Kit. Subcon-
fluent human embryonic kidney (HEK293T) cells, cul-
tured in 75 cm2 flasks, were transfected with 6 ml of
DMEM containing 9 μg of plasmid and 21 μl of
Lipofectamine LTX Reagent (Invitrogen), according to
a standard protocol [22]. After the cells were incubated
for 6 h at 37 °C under 5 % CO2, the transfection
medium was replaced with 6 ml of protein-free medium
(EX CELL 293; Sigma-Aldrich) and the flasks were
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incubated as described above for a further 48 h. The
medium was collected, centrifuged at 3000 × g for
10 min to remove the cell debris, and stored at –80 °C
until analysis. Because the protein was expressed as a
fusion protein, with a 6 × His tail, the protein concen-
tration was roughly estimated using serial twofold dilu-
tions in an indirect ELISA test coating of each
supernatant into wells and probed with an anti-6 × His
monoclonal antibody. A known amount of serially di-
luted recombinant 6 × His-tail-fused protein was used
as the positive control to generate a standard curve, as
previously described [21]. The complete sequence of
the PCR fragment included 1158 bp of the gE ectodo-
main sequence, equivalent to 386 amino acids (patent
pending: IT TO2014A000366). Protein expression was
evaluated using a monoclonal antibody directed against
the 6 × His tail. A 1:10 dilution of the cell supernatant
was optimal for the test optimization (data not shown).
The recombinant BoHV1 gE protein (medium from
transfected cultures, even wells) or negative antigen
(conditioned medium from untransfected cultures, odd
wells) were diluted 1:10 in 0.1 M carbonate/bicarbonate
buffer (pH 9.6) and used to coat the wells of a Nunc
Maxisorp plate overnight at 4 °C. After the wells were
blocked with 2.5 % bovine casein, the serum samples
diluted 1:20 in phosphate-buffered saline (PBS)/1.25 %
casein were added to the wells and the plates were in-
cubated for 1 h at room temperature. After a washing
step, peroxidase-labeled protein G, diluted to 10 ng/ml
in PBS/1.25 % casein, was added and the plates were in-
cubated for 45 min at room temperature. After the final
wash, the color reaction was developed with 3,3′,5,5’-
tetramethylbenzidine and stopped with 0.2 M H2SO4.
The results were calculated as the percentage of serum
reactivity compared with the positive controls (S/P) in-
cluded in each plate. The cut-off value was determined
by plotting the ROC curve and identifying the best sen-
sitivity/specificity performance based on the reactivity
of 189 gE-positive sera and 423 gE-negative sera. The
ROC curve was drawn with the ROCR package of the R
statistical software [23, 24].
Serum samples
Different sets of blood serum samples from cattle were
included in this study, collected from the Italian regions
of Piedmont and Veneto. Among the samples, the field
sera were collected during official surveillance proce-
dures (n = 189), and the sera from experimentally in-
fected animals (n = 7) were collected at different times
and tested. Experimental infection was included in
project no. 5885, on 09/07/2009, approved by the Ethics
Committee of the Istituto Zooprofialttico Sperimentale
delle Venezie according to article 7 of Decree No. 116,
dated 27th January 1992.
All these sera were classified as positive based on the
results of a commercially available whole-virus indirect
ELISA (SVANOVA Svanovir IBR-Ab, IDEXX Trachitest
Serum Screening Ab Test) and gB and/or gE blocking
ELISAs (IDEXX IBR gE ab and gB Ab tests) . To evalu-
ate analytical sensitivity, a small subset of sera from the
field collection (n = 3) and all the sera from the experi-
mentally infected animals were also serially diluted (two-
fold) in negative serum, and tested with the procedure
described above.
The gE-negative serum set included 460 samples
from both marker-vaccinated (n = 33) and IBR-free
cattle (n = 427). All the sera from IBR-free cattle were
negative when tested with two different commercially
available gE blocking ELISAs and were expected to be
negative on the rec-gE indirect ELISA. A subset of
negative sera (n = 16) was selected because they gener-
ated false-positive outcomes when tested with a com-
mercially available gE blocking ELISA. The true
negative status of this subset was confirmed by repeat-
ing the sample collection and ELISAs (both blocking
and whole-antigen indirect ELISAs), and epidemio-
logical investigations at the herd level. This subset of
samples was used to verify the independence of the
proposed rec-gE indirect ELISA relative to the diagnos-
tic blocking ELISA.
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